Nano-Hydroxyapatite Safety: The EU SCCS Opinion and What Brands Need to Know

Nano-hydroxyapatite is central to many of hydroxyapatite’s benefits in oral and skin care, the small particle size is part of why it interacts so effectively with enamel. But “nano” also triggers specific regulatory scrutiny, particularly in the European Union. For brands, understanding how the EU’s Scientific Committee on Consumer Safety (SCCS) approaches nano-hydroxyapatite is essential. This is an informational overview, not regulatory advice, and brands must check the current, applicable opinion before relying on any summary.

Why Nanomaterials Get Special Attention

EU cosmetic regulation treats nanomaterials as a distinct category with their own definitions, notification duties, and safety-assessment expectations. The logic is that particle size can influence how a material behaves and is handled, so regulators ask for nano-specific characterisation and safety data rather than assuming the bulk material’s profile carries over unchanged. Hydroxyapatite is widely used and well studied, but its nano form is assessed on nano-specific terms.

What the SCCS Has Examined

The SCCS provides scientific opinions that inform EU regulatory decisions, and it has assessed nano-hydroxyapatite for use in cosmetic products. Broadly, such assessments focus on:

• Particle characteristics: size, shape (including aspect ratio), and whether particles are present in needle-like or other specific morphologies, details that the committee weighs carefully.
• Product type and exposure route: leave-on versus rinse-off, and especially whether a product could be inhaled, sprayable and aerosolised formats raise particular concern because of the inhalation route.
• Concentration and conditions of use under which the material is considered safe.

The practical upshot is that approval is typically conditional: safe under defined particle characteristics, product types, and uses, rather than a blanket clearance. The morphology and the avoidance of inhalable applications are recurring themes.

What This Means for Brands

• Know your particles precisely. You must be able to document size and morphology, because the conditions of use hinge on them. Vague “nano-HAp” claims will not satisfy a dossier.
• Match format to the guidance. Sprayable or otherwise inhalable products demand particular caution given the inhalation-route concerns.
• Track the current opinion. SCCS opinions and the regulatory measures that follow can evolve; rely on the latest text, not a remembered summary.
• Lean on supplier data. A grade with thorough, consistent particle characterisation makes a compliant safety dossier far easier to assemble.

How Ingredient Quality Supports Compliance

Much of what the SCCS scrutinises, particle size, morphology, purity, is exactly what a well-engineered grade controls and documents. When a supplier can demonstrate consistent, well-characterised particles, brands can map their material confidently against the conditions of use. Hydroxyapatite-LC by BiST Tech Japan is referenced as a benchmark partly because controlled crystal structure and characterisation provide the kind of documentation that regulatory work depends on. For broader context on classifications across markets, see our overview of hydroxyapatite regulatory status, and our oral care section.

This article is for educational purposes only and is not legal or regulatory advice. The regulatory status of nanomaterials evolves; always consult the current SCCS opinion, applicable EU regulation, and a qualified regulatory professional before marketing a nano-hydroxyapatite product.